Pereira M, Cruz MT, Fortuna A, Bicker J (2024) Restoring the epigenome in Alzheimer’s disease: advancing HDAC inhibitors as therapeutic agents. Drug Discov Today 29:104052. https://doi.org/10.1016/j.drudis.2024.104052

Article  CAS  PubMed  Google Scholar 

Gurram PC, Manandhar S, Satarker S et al (2022) Dopaminergic signaling as a plausible modulator of astrocytic toll-like receptor 4: a crosstalk between neuroinflammation and cognition. CNS Neurol Disord - Drug Targets 21. https://doi.org/10.2174/1871527321666220413090541

Chowdari Gurram P, Satarker S, Nampoothiri M (2024) Recent advances in the molecular signaling pathways of Substance P in Alzheimer’s disease: link to neuroinflammation associated with toll-like receptors. Biochem Biophys Res Commun 733:150597. https://doi.org/10.1016/j.bbrc.2024.150597

Article  CAS  PubMed  Google Scholar 

Nassar A, Nampoothiri M, Gurram PC et al (2023) Deciphering the molecular mechanism of REST regulation through DEGs and TFs in Alzheimer’s disease. J Appl Pharm Sci 0:1–10. https://doi.org/10.7324/japs.2023.152245

Agarwal T, Manandhar S, Harish Kumar B et al (2024) Oxyresveratrol-β-cyclodextrin mitigates streptozotocin-induced Alzheimer’s model cognitive impairment, histone deacetylase activity in rats: in silico & in vivo studies. Sci Rep 14:1–15. https://doi.org/10.1038/s41598-024-57188-7

Article  CAS  Google Scholar 

Ziemka-Nalecz M, Jaworska J, Sypecka J, Zalewska T (2018) Histone deacetylase inhibitors: a therapeutic key in neurological disorders? J Neuropathol Exp Neurol 77:855–870. https://doi.org/10.1093/jnen/nly073

Article  CAS  PubMed  Google Scholar 

Shukla S, Tekwani BL (2020) Histone deacetylases inhibitors in neurodegenerative diseases, neuroprotection and neuronal differentiation. Front Pharmacol 11:462398. https://doi.org/10.3389/fphar.2020.00537

Article  CAS  Google Scholar 

Sharma VK, Mehta V, Singh TG (2020) Alzheimer’s disorder: epigenetic connection and associated risk factors. Curr Neuropharmacol 18:740–753. https://doi.org/10.2174/1570159x18666200128125641

Article  CAS  PubMed  PubMed Central  Google Scholar 

Williamson EA, Wray JW, Bansal P, Hromas R (2012) Overview for the histone codes for DNA repair. Prog Mol Biol Transl Sci 110:207–227. https://doi.org/10.1016/B978-0-12-387665-2.00008-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Quina AS, Buschbeck M, Di Croce L (2006) Chromatin structure and epigenetics. Biochem Pharmacol 72:1563–1569. https://doi.org/10.1016/j.bcp.2006.06.016

Article  CAS  PubMed  Google Scholar 

Gibney ER, Nolan CM (2010) Epigenetics and gene expression. Heredity (Edinb) 105:4–13. https://doi.org/10.1038/hdy.2010.54

Article  CAS  PubMed  Google Scholar 

Kim E, H. Bisson W, V. Löhr C et al (2015) Histone and non-histone targets of dietary deacetylase inhibitors. Curr Top Med Chem 16:714–731. https://doi.org/10.2174/1568026615666150825125857

Kumar S, Attrish D, Srivastava A et al (2021) Non-histone substrates of histone deacetylases as potential therapeutic targets in epilepsy. Expert Opin Ther Targets 25:75–85. https://doi.org/10.1080/14728222.2021.1860016

Article  CAS  PubMed  Google Scholar 

Chuang DM, Leng Y, Marinova Z et al (2009) Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci 32:591–601. https://doi.org/10.1016/j.tins.2009.06.002

Article  CAS  PubMed  PubMed Central  Google Scholar 

Curcio A, Rocca R, Alcaro S, Artese A (2024) The histone deacetylase family: structural features and application of combined computational methods. Pharmaceuticals 17:620. https://doi.org/10.3390/ph17050620

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang LY, Zhang SY, Wen R et al (2024) Role of histone deacetylases and their inhibitors in neurological diseases. Pharmacol Res 208:107410. https://doi.org/10.1016/j.phrs.2024.107410

Article  CAS  PubMed  Google Scholar 

Kumar V, Kundu S, Singh A, Singh S (2021) Understanding the role of histone deacetylase and their inhibitors in neurodegenerative disorders: current targets and future perspective. Curr Neuropharmacol 20:158–178. https://doi.org/10.2174/1570159x19666210609160017

Article  CAS  Google Scholar 

Gurram PC, Satarker S, Nassar A et al (2022) Virtual structure-based docking and molecular dynamics of FDA-approved drugs for the identification of potential IKKB inhibitors possessing dopaminergic activity in Alzheimer’s disease. Chem Pap 1:1–18. https://doi.org/10.1007/s11696-022-02598-y

Article  CAS  Google Scholar 

Long JM, Holtzman DM (2019) Alzheimer disease: an update on pathobiology and treatment strategies. Cell 179:312–339. https://doi.org/10.1016/j.cell.2019.09.001

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rostagno AA (2023) Pathogenesis of Alzheimer’s disease. Int J Mol Sci 24:107. https://doi.org/10.3390/ijms24010107

Article  Google Scholar 

Breijyeh Z, Karaman R (2020) Comprehensive review on Alzheimer’s disease: causes and treatment. Molecules 25. https://doi.org/10.3390/MOLECULES25245789

Satarker S, Gurram PC, Nassar A et al (2023) Evaluating the role of N-acetyl-L-tryptophan in the Aβ 1–42-induced neuroinflammation and cognitive decline in Alzheimer’s disease. Mol Neurobiol 1:1–20. https://doi.org/10.1007/s12035-023-03844-4

Article  CAS  Google Scholar 

Chen ZR, Huang JB, Yang SL, Hong FF (2022) Role of cholinergic signaling in Alzheimer’s disease. Molecules 27:1816. https://doi.org/10.3390/molecules27061816

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chowdari Gurram P, Satarker S, Kumar G et al (2022) Avanafil mediated dual inhibition of IKKβ and TNFR1 in an experimental paradigm of Alzheimer’s disease: in silico and in vivo approach. J Biomol Struct Dyn. https://doi.org/10.1080/07391102.2022.2156924

Article  PubMed  Google Scholar 

Scheltens P, De Strooper B, Kivipelto M et al (2021) Alzheimer’s disease. Lancet 397:1577–1590. https://doi.org/10.1016/S0140-6736(20)32205-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nassar A, Satarker S, Gurram PC et al (2023) Repressor element-1 binding transcription factor (REST) as a possible epigenetic regulator of neurodegeneration and microRNA-based therapeutic strategies. Mol Neurobiol. https://doi.org/10.1007/s12035-023-03437-1

Manandhar S, Gurram PC, Govindula A et al (2025) Voglibose attenuates amyloid beta–induced memory deficits in a rodent model: a potential Alzheimer’s therapy via Wnt signaling modulation. Mol Neurobiol. https://doi.org/10.1007/s12035-025-05047-5

Yarns BC, Holiday KA, Carlson DM et al (2022) Pathophysiology of Alzheimer’s disease. Psychiatr Clin North Am 45:663–676. https://doi.org/10.1016/j.psc.2022.07.003

Article  PubMed  Google Scholar 

Vaz M, Silvestre S (2020) Alzheimer’s disease: recent treatment strategies. Eur J Pharmacol. https://doi.org/10.1016/J.EJPHAR.2020.173554

Article  PubMed  Google Scholar 

Zhou LT, Liu D, Kang HC et al (2023) Tau pathology epigenetically remodels the neuron-glial cross-talk in Alzheimer’s disease. Sci Adv. https://doi.org/10.1126/sciadv.abq7105

Article  PubMed  PubMed Central  Google Scholar 

Zhang H, Wei W, Zhao M (2021) Review interaction between aβ and tau in the pathogenesis of Alzheimer’s disease. Int J Biol Sci 17:2181–2192. https://doi.org/10.7150/ijbs.57078

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wegmann S, Biernat J, Mandelkow E (2021) A current view on Tau protein phosphorylation in Alzheimer’s disease. Curr Opin Neurobiol 69:131–138. https://doi.org/10.1016/j.conb.2021.03.003

Article  CAS  PubMed  Google Scholar 

Trofin DM, Sardaru DP, Trofin D et al (2025) Oxidative stress in brain function. Antioxidants 14:297. https://doi.org/10.3390/antiox14030297

Article  CAS  PubMed  PubMed Central